The Acromegaly drugs in development market research report provides comprehensive information on the therapeutics under development for Acromegaly, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Acromegaly. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Acromegaly and features dormant and discontinued products.

GlobalData tracks 17 drugs in development for Acromegaly by 16 companies/universities/institutes. The top development phase for Acromegaly is phase i with seven drugs in that stage. The Acromegaly pipeline has 17 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Acromegaly pipeline products market are: ASCIL Biopharm, Debiopharm International and CASI Pharmaceuticals.

The key targets in the Acromegaly pipeline products market include Somatostatin Receptor Type 2 (SRIF1 or SSTR2), Somatostatin Receptor Type 5 (SSTR5), and Growth Hormone Receptor (Somatotropin Receptor or GHR).

The key mechanisms of action in the Acromegaly pipeline product include Somatostatin Receptor Type 2 (SRIF1 or SSTR2) Agonist with ten drugs in Phase III. The Acromegaly pipeline products include five routes of administration with the top ROA being Subcutaneous and five key molecule types in the Acromegaly pipeline products market including Synthetic Peptide, and Antisense Oligonucleotide.

Acromegaly overview

Acromegaly is a hormonal disorder that develops when pituitary gland produces too much growth hormone during adulthood. Symptoms include body odor, easy fatigue, headache, large feet, excessive height, swelling of the bony areas around a joint, widely spaced teeth, and sleep apnea. Treatment includes surgery, dopamine agonists, and growth hormone antagonists.

For a complete picture of Acromegaly’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.